Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07535268 · ClinicalTrials.gov registry record
REPRESENT-PF Registry
A clinical trial, sponsored by Vivek Reddy.
- Recruiting
- Registry status
- 275
- Enrollment target
NCT07535268: Recruiting study, sponsored by Vivek Reddy.
NCT07535268 is a clinical trial that is actively recruiting participants, run by Vivek Reddy. The registered enrollment target is 275 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07535268 is actively recruiting participants, sponsored by Vivek Reddy.
- RECRUITING
- Registry status
- 275 participants
- Enrollment target
Study Summary
This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.
Primary Outcome
Assess device- or procedure-related Composite Serious Adverse Events (CSAEs) assessed through Day 60 following the Ablation Procedure The proportion of all Treatment Subjects and Attempt Subjects (combined PAF and PersAF cohort) with one or more device- or procedure-related Composite Serious Adverse Events (CSAEs) assessed through Day 60 following the Ablation Procedure on or prior to the Day 60 Assessment, with an Onset Date following the procedure.
Interventions
- DEVICE FARAWAVE Pulsed Field Ablation Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2026-03-30 |
| Est. Completion | 2028-03-01 |
What NCT07535268 shows while recruiting
NCT07535268 is an observational study that tracks outcomes without assigning an intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which FARAWAVE Pulsed Field Ablation Catheter is the first listed.
NCT07535268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07535268 about?
NCT07535268 is a clinical study titled "REPRESENT-PF Registry". This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of ca...
What is the current status of trial NCT07535268?
This trial is currently recruiting. The enrollment target is 275 participants. The study started on 2026-03-30. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07535268?
The interventions under investigation include: FARAWAVE Pulsed Field Ablation Catheter (DEVICE).
Who is sponsoring clinical trial NCT07535268?
This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI